according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

#### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Mometasone / Clotrimazole / Gentamicin Formulation

Other means of identification : MOMETAMAX OINTMENT (52269)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

1-908-423-6000

#### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A H360D: May damage the unborn child.

Short-term (acute) aguatic hazard, Cate- H400: Very toxic to aguatic life.

gory 1

Long-term (chronic) aquatic hazard, Cat-H411: Toxic to aquatic life with long lasting effects.

egory 2

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Hazard pictograms :

¥2

Signal word : Danger

Hazard statements : H360D May damage the unborn child.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

#### Hazardous components which must be listed on the label:

Gentamicin

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
clotrimazole	23593-75-1	Acute Tox. 4; H302	1
	245-764-8	Acute Tox. 3; H311	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878  $\,$ 



# Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

		Eye Irrit. 2; H319 Repr. 2; H361fd STOT RE 2; H373 (Liver, Kidney, Adrenal gland) Aquatic Acute 1; H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10  Acute toxicity estimate  Acute dermal toxicity: 923 mg/kg	
Gentamicin	1403-66-3 215-765-8	Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute	0.3
		aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 1	
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410	0.1
		M-Factor (Chronic aquatic toxicity): 100	

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

#### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 415340-00027 Date of first issue: 14.12.2015 6.1

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

**Environmental precautions** Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

## 6.3 Methods and material for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material.

> For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## **SECTION 7: Handling and storage**

## 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
White mineral oil (petroleum)	8042-47-5	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL	
clotrimazole	23593-75-1	TWA	0.2 mg/m3 (OEB 2)	Internal	
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)	Internal	
	Further information: OTO				
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal	
	Further information: Skin				
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal	

#### 8.2 Exposure controls

#### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Filter type : Combined particulates and organic vapour type (A-P)

## **SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

Physical state : suspension

Colour : white to off-white

Odour : oily

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

Relative density : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

#### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact

Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

#### **Product:**

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

**Components:** 

clotrimazole:

Acute oral toxicity : LD50 (Rat): 708 mg/kg

LD50 (Mouse): 761 mg/kg

LD50 (Rabbit): > 1,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.73 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Mouse): 923 mg/kg

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg

LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

administration)

LD50 (Rat): 67 - 96 mg/kg Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg

Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of:

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous Symptoms: Breathing difficulties

#### Skin corrosion/irritation

Not classified based on available information.

#### **Components:**

clotrimazole:

Species : Rabbit

Result : No skin irritation

Gentamicin:

Species : Rabbit

Result : Mild skin irritation

Mometasone:

Species : Rabbit

Result : No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

### **Components:**

clotrimazole:

Species : Rabbit

Result : Mild eye irritation

Gentamicin:

Species : Rabbit

Result : Mild eye irritation

Mometasone:

Species : Rabbit

Result : No eye irritation

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

### **Respiratory sensitisation**

Not classified based on available information.

**Components:** 

Gentamicin:

Remarks : No data available

Mometasone:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

#### Germ cell mutagenicity

Not classified based on available information.

**Components:** 

clotrimazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat

Application Route: Oral

Result: negative

Test Type: Mammalian spermatogonial chromosome aberra-

tion test (in vivo) Species: Hamster Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### clotrimazole:

Species : Rat
Application Route : Oral
Exposure time : 78 weeks

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Result : negative

Gentamicin:

Carcinogenicity - Assess-

ment

No data available

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

Reproductive toxicity

May damage the unborn child.

**Components:** 

clotrimazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 50 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 50 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 415340-00027 Date of first issue: 14.12.2015 6.1

Application Route: Oral

Developmental Toxicity: NOAEL: 180 mg/kg body weight

Result: No effects on foetal development

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments.. Some evidence of adverse effects on development, based on animal experi-

ments.

Gentamicin:

Effects on fertility Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3.6 mg/kg body weight

Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

Mometasone:

Effects on fertility Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced foetal

weight

Result: No effects on fertility, Effect on reproduction capacity

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 6.1
 28.09.2024
 415340-00027
 Date of first issue: 14.12.2015

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

#### STOT - single exposure

Not classified based on available information.

#### **Components:**

#### Mometasone:

Remarks : Based on available data, the classification criteria are not met.

#### STOT - repeated exposure

Not classified based on available information.

#### Components:

#### clotrimazole:

Target Organs : Liver, Kidney, Adrenal gland

Assessment : May cause damage to organs through prolonged or repeated

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

exposure.

Gentamicin:

Target Organs : Kidney, inner ear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

#### **Components:**

clotrimazole:

Species : Rabbit
LOAEL : 5 - 40 mg/kg
Application Route : Skin contact
Exposure time : 3 Weeks
Target Organs : Skin

Symptoms : Oedema, Fissuring, Necrosis, Redness

Species : Rat
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 18 Months

Target Organs : Liver, Kidney, Adrenal gland

Species : Dog LOAEL : 25 mg/kg Application Route : Oral

Exposure time : 6 - 12 Months Target Organs : Adrenal gland

Symptoms : Salivation, Lachrymation, Vomiting

Gentamicin:

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

Symptoms : Vomiting, Salivation

Species : Monkey LOAEL : 50 mg/kg Application Route : Subcutaneous

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 6.1
 28.09.2024
 415340-00027
 Date of first issue: 14.12.2015

Exposure time : 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 10 mg/kg

Application Route : Intramuscular

Exposure time : 52 Weeks

Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12.5 mg/kg

LOAEL : 50 mg/kg

Application Route : Intramuscular

Exposure time : 13 Weeks

Target Organs : Kidney

Mometasone:

Species : Rat

NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog LOAEL : 0.5 mg/kg Application Route : Oral Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0.00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species : Dog NOAEL : 0.0005 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

#### **Aspiration toxicity**

Not classified based on available information.

#### **Components:**

#### Mometasone:

Not applicable

#### 11.2 Information on other hazards

### **Endocrine disrupting properties**

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

#### **Components:**

clotrimazole:

Skin contact : Symptoms: Rash, Itching, Blistering, Oedema, Redness Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

**Further information** 

**Components:** 

Mometasone:

Remarks : Dermal absorption possible

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

### **SECTION 12: Ecological information**

#### 12.1 Toxicity

**Components:** 

clotrimazole:

Toxicity to fish : LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.02 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/l

Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 0.017 mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

icity)

10

Toxicity to microorganisms : EC50 : > 10,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.025 mg/l

Exposure time: 32 d

Species: Oncorhynchus mykiss (rainbow trout)

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chronic toxicity)

NOEC: 0.01 mg/l

Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

10

Gentamicin:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): 10 μg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

plants Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5

μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

100

Toxicity to microorganisms : EC50 : 288.7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

M-Factor (Chronic aquatic

toxicity)

: 1

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.00014 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.34 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

100

#### 12.2 Persistence and degradability

#### **Components:**

clotrimazole:

Stability in water : Hydrolysis: 50 %(242 d)

Gentamicin:

Biodegradability : Result: rapidly degradable

Biodegradation: 100 % Exposure time: 28 d

Method: OECD Test Guideline 314

Mometasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)

Method: OECD Test Guideline 111

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

#### 12.3 Bioaccumulative potential

#### Components:

Gentamicin:

Partition coefficient: n-

octanol/water

: log Pow: < -2

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.68

#### 12.4 Mobility in soil

### Components:

Mometasone:

Distribution among environ-

mental compartments

: log Koc: 4.02

#### 12.5 Results of PBT and vPvB assessment

### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Endocrine disrupting properties

### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(clotrimazole, Gentamicin)

### 14.3 Transport hazard class(es)

Class Subsidiary risks

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

#### 14.4 Packing group

**ADN** 

Packing group : III Classification Code : M6

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

Hazard Identification Number : 90 Labels : 9

**ADR** 

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

**RID** 

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

**IMDG** 

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 964

ger aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

**ADR** 

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

**IMDG** 

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

#### **SECTION 15: Regulatory information**

## 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not. Not applicable

Not applicable

Not applicable

Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2 ENVIRONMENTAL 100 t 200 t

E1 ENVIRONMENTAL 100 t

**HAZARDS** 

#### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 415340-00027 Date of first issue: 14.12.2015 6.1

The components of this product are reported in the following inventories:

**AICS** : not determined

DSL not determined

**IECSC** not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H302 Harmful if swallowed. H311 Toxic in contact with skin. H319 Causes serious eye irritation. H360D May damage the unborn child.

H360Df May damage the unborn child. Suspected of damaging fertili-

H361fd Suspected of damaging fertility. Suspected of damaging the

unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H373 May cause damage to organs through prolonged or repeated

exposure if inhaled.

May cause damage to organs through prolonged or repeated H373

exposure if swallowed.

H400 Very toxic to aquatic life.

Very toxic to aquatic life with long lasting effects. H410

#### Full text of other abbreviations

Acute Tox. Acute toxicity

Aquatic Acute Short-term (acute) aquatic hazard Long-term (chronic) aquatic hazard Aquatic Chronic

Eve Irrit. Eve irritation Repr.

Reproductive toxicity

STOT RE Specific target organ toxicity - repeated exposure IE OEL

Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regula-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015

tion (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to : compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

#### Classification of the mixture: Classification procedure:

Repr. 1A H360D Calculation method
Aquatic Acute 1 H400 Calculation method
Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878  $\,$ 



# Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 6.1 28.09.2024 415340-00027 Date of first issue: 14.12.2015